The Technical AnalystExchange: STO Sector: Healthcare Industry: Diagnostics & Research
SenzaGen AB Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.97% SEK9.32
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 224.28 mill |
| EPS: | -0.910 |
| P/E: | -10.24 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 24.06 mill |
| Avg Daily Volume: | 0.0240 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.24 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -10.24 | industry: PE 48.39 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
SEK 8.88 - 9.76 ( +/- 4.74%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK9.32 (1.97% ) |
| Volume | 0.0330 mill |
| Avg. Vol. | 0.0240 mill |
| % of Avg. Vol | 137.48 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SENZA.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SENZA.ST
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.